Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: Histopathological and microbiological study

International Journal of Leprosy and Other Mycobacterial Diseases

Volumn 67, Issue 3, 1999, Pages 292-297

  Ebenezer, Gigi J ^a   Job, Anand ^b   Abraham, Suneetha ^a   Arunthathi, S ^a   Sundar Rao, P S S ^a   Job, Charles K ^a  

^a Schieffelin Leprosy Res/Train Ctr   (India)

^b CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LEPROSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; FOOT PAD; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDIA; LEPROSY; MOUSE; MYCOBACTERIUM LEPRAE; NONHUMAN; SKIN BIOPSY; TREATMENT OUTCOME;

ADULT; ANIMALS; BIOLOGICAL ASSAY; CLOFAZIMINE; DAPSONE; DRUG THERAPY, COMBINATION; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MALE; MICE; MIDDLE AGED; MYCOBACTERIUM LEPRAE; NASAL MUCOSA; RIFAMPIN; SKIN;

EID: 0032696911     PISSN: 0148916X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. DESIKAN, K. V. Viability of Mycobacterium leprae outside the human body. Lepr. Rev. 48 (1977) 231-235.
2. GANAPATHI, R., REVANKAR, C. R. and RASHMI, R. P. Three years assessment of multidrug therapy in multibacillary leprosy cases. Indian J. Lepr. 57 (1987) 44-49.
3. MARCHOUX CHEMOTHERAPY STUDY GROUP. Relapses in multibacillary leprosy patients after stopping treatment with rifampin-containing combined regimens. Int. J. Lepr. 60 (1992) 525-535.
4. NOORDEEN, S. K. The epidemiology of leprosy. In: Leprosy. 2nd edn. Hastings, R. C., ed. Edinburgh: Churchill Livingstone, 1994, p. 37.
5. PATTYN, S. R., BOURLAND, J., GRILLONE, S. and JANSSENS, L. Multibacillary leprosy can be treated by a fixed duration therapy. (Abstract) Int. J. Lepr. 57 Suppl. (1989) 428.
6. SIVAPRASAD, N., SNEHALATHA, S., LOBO, D., ASCHHOFF, M. and JOB, C. K. Viability of Mycobacterium leprae in lepromatous patients after 5 years of dapsorie monotherapy supplemented with 2 years of multidrug therapy. Indian J. Lepr. 67 (1995) 427-433.
7. THELEP SUBCOMMITTEE ON CLINICAL TRIAL OF CHEMOTHERAPY OF LEPROSY. Scientific Working Group UNDP/World Bank WHO Special Programme for Research and Training in Tropical Diseases. Persisting M. leprae among THELEP trial patients in Bamako and Chinglepet. Lepr. Rev. 58 (1987) 325-327.
8. WHO DOCUMENT. TDR/SWG - THELEP (1)/77.3, Annex I, Appendix 5.10. Geneva: World Health Organization, 1977.
9. WHO STUDY GROUP. Chemotherapy of leprosy for control programmes. Geneva: World Health Organization, 1982, p. 23. Tech. Rep. Ser. 675.
10. WHO STUDY GROUP. Chemotherapy of leprosy. Geneva: World Health Organization, 1994, p. 12. Tech. Rep. Ser. 847.
11. WHO ACTION PROGRAMME FOR THE ELIMINATION OF LEPROSY. Status report updated. Geneva: World Health Organization, 1997, pp. 7-10. WHO/LEP/97.4.